Yuanmei Lu

Yuanmei Lu is special counsel in the Corporate Practice Group in the firm’s Shanghai office. 

Areas of Practice

Yuanmei specializes in representing investment funds, institutional investors and portfolio companies on a wide variety of corporate transactions, including convertible note and SAFE financings; preferred stock financings; growth equity investments; secondary sales of founder equity; mergers and acquisitions; and fund formation and management.

Yuanmei also represents publicly-held companies, especially foreign private issuers, with their 1934 Act reporting obligations and with NASDAQ, NYSE and other exchange listing and compliance matters.

Yuanmei has worked with investors and companies in a variety of industries, including semiconductors, life sciences, technology, biotech, video games, beauty and personal care, and consumer goods.

Honors

• Thought Leader, China – Intellectual Property, Mondaq, 2022

Articles

China Law Update Blog

• "China Revised Rules for Foreign Investors’ Strategic Investment in A-share Listed Companies," November 11, 2024
• "China Launched Pilot Program Permitting Foreign Enterprises’ Greater Participation in Value-Added Telecommunications Services," November 6, 2024
• "China Expands Pilot Program for Foreign Investment in the Healthcare Sector," September 9, 2024
• "China Proposed New Anti-Monopoly Guidelines for the Pharmaceutical Sector," August 27, 2024

• "Highlights of the Draft Amendment to the Arbitration Law of China," August 20, 2024
• "China to Implement Export Controls on Aerospace Technology, Software, and Equipment," June 4, 2024
• "Amendment to China’s Company Law (1): Contribution of Capital and Authorized Capital Concept," April 19, 2024

• "China Issues Regulations on Facilitating and Regulating Cross-Border Data Flow," April 11, 2024
• "Companies in Beijing are Submitting Application Materials Relating to the Security Assessment for Cross-border Data Transfer," January 22, 2024
• "China Released Draft Rules Regulating and Promoting Cross-Border Data Transfer," November 16, 2023
• "Overview of Recent Anti-Corruption Enforcement Actions in the Pharmaceutical Industry in China," September 27, 2023

• "Regulatory Framework for Privately-Offered Investment Funds in China: Implications and Compliance," July 24, 2023
• "China Issues Security Assessment Measures of Data Cross-border Transfer," August 10, 2022

• "China Securities Regulatory Commission issued Proposed Provisions Related to Offshore Listing," June 29, 2022
• "International Cooperation under China’s Proposed Implementing Rules for Human Genetic Resources Management," April 29, 2022
• "China Proposed Draft Implementing Rules for Human Genetic Resources Management," April 18, 2022
• "Provisions on Administration of Algorithmic Recommendation Took Effect on March 1," March 23, 2022
• "Cross-Border Transfer of Personal Information under China’s Cybersecurity Law," February 28, 2022
• "China Issued Amended Cybersecurity Review Measures," February 14, 2022
• "China Issued 2021 Version of Negative List for Foreign Investment," January 31, 2022
• "China Securities Regulatory Commission Issued Proposed Rules on Offshore Listing," January 13, 2022
• "Hong Kong Stock Exchange Announced New Listing Regime for SPAC," December 30, 2021
• "Overview on China’s New Draft Measures for Data Cross-border Transfer," November 5, 2021
• "Highlights of China’s Recently Adopted Personal Information Protection Law," August 24, 2021

Global Trade Law Blog

• "Executive Orders on Pause: WeChat and TikTok Bans Temporarily Suspended," September 21, 2020